The company is releasing insulin vials and pens under its ReliOn house brand. They'll show up in Walmart pharmacies this week. Jessica was a writer on the Wellness team, with a focus on health ...
Retail conglomerate Walmart announced the creation of its own brand of analog insulin to offer diabetics a more affordable option than the expensive brand name versions. “We know many people with ...
Walmart announced Tuesday it will start selling private-label insulin this summer at a much lower price for the lifesaving diabetes drug than branded varieties in vials and pens. The new brand, called ...
California began partnering with Civica in 2023 for its “CalRx” brand of insulin and put $50 million toward its development, the company said. Starting in the new year, insulin pens will be available ...
A smart insulin pen may not be the rarest sighting in diabetes these days, but Bigfoot Biomedical aims to stand apart with a new FDA clearance for delivery devices that provide real-time alerts for ...
LOS ANGELES (AP) — Gov. Gavin Newsom said Thursday that California will begin selling affordable insulin under its own label on Jan. 1, nearly three years after he first announced a partnership to ...
The Bigfoot Unity System uses iCGM data from Abbott’s FreeStyle Libre 2 system and consists of smart pen caps for rapid- and long-acting insulin, as well as a mobile app. The Food and Drug ...
California’s CalRx insulin pens will launch Jan. 1 at $11 each, or $55 for a five-pack The state has invested $100 million to lower insulin costs The effort could save patients $2,000 to $4,000 a year ...
Abbott Laboratories, Inc. ABT recently completed its previously announced acquisition of Bigfoot Biomedical — a developer of intelligent insulin management systems for people with diabetes. Financial ...
The state’s insulin — sold under the brand name CalRx — will be available at a recommended price of $11 per pen, or $55 for a five-pack. The move is part of a partnership between the state and the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results